The concept of adaptive licensing as a means of making innovative medicines available faster is generating much excitement, but some drug companies are worried about how this emerging approach might be implemented. Lynn Baird and Gigi Hirsch say their concerns can be overcome.
The concept of adaptive licensing as a means of making innovative medicines available faster is generating much excitement, but some drug companies are worried about how this emerging approach might be implemented. Lynn Baird and Gigi Hirsch say their concerns can be overcome.
The perceived merits and weaknesses of an adaptive licensing approach for approving medicines are being widely discussed around the world.
Create an account to read this article
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
As more medicines come off patent in the coming years, the UK generics and biosimilars industry association is hoping to see more generic products evaluated for reimbursement by the health technology assessment institute, NICE.
Sam Roberts, chief executive of England’s NICE, has defended the health technology assessment institute’s cost-effectiveness thresholds and the country’s ranking against other nations when it comes to market access, while acknowledging that the UK’s pharma ecosystem is “really tough.”
The 27-year agency veteran has not been formally approached about filling the vacancy created by George Tidmarsh’s resignation, but also is not interested in the position, the Pink Sheet has learned.
